-
1.发明公开AMELIORATION OF METABOLIC SYNDROME OR METHOD FOR SCREENING FOR AMELIORATING AGENT FOR METABOLIC SYNDROME UTILIZING PHYSIOLOGICAL FUNCTION OF SPHINGOMYELIN SYNTHASE SMS2 审中-公开代谢综合征或方法，以筛选缓解代谢综合征救济资金使用鞘磷脂合成酶SMS2生理功能
公开(公告)号：EP2481808A1
公开(公告)日：2012-08-01
申请号：EP10818555.4
申请日：2010-09-22
发明人： MITSUTAKE, Susumu , IGARASHI, Yasuyuki , ZAMA, Kota , YOSHIDA, Tetsuya , TANAKA, Yoshikazu , TAKEMOTO, Hiroshi
CPC分类号： C12Q1/48 , G01N2333/9129 , G01N2800/044
摘要： Disclosed is a method for screening for a medicinal agent that can decrease a body weight, a medicinal agent that can reduce a visceral fat, a medicinal agent that can reduce a triglyceride in the liver, and a medicinal agent that can ameliorate obesity and fatty liver. The method involves a step of measuring the inhibitory activity of a candidate substance on a sphingomyelin synthase, wherein the candidate substance is determined to have at least one function selected from the group consisting of an anti-obesity agent, a visceral fat-reducing agent, a fatty liver-treating agent and an adiponectin expression enhancer when the candidate substance has an inhibitory activity on the sphingomyelin synthase.
摘要翻译： 本发明公开了一种筛选的药剂也可以减少体重的方法，药剂确实可以减少内脏脂肪，药剂确实能减少肝脏甘油三酯和药剂也可以改善肥胖和脂肪肝 ， 该方法包括测量在鞘磷脂合酶的候选物质的抑制活性，worin所述候选物质的步骤是确定性的开采具有选自抗肥胖剂中的至少一种功能，内脏脂肪减少剂， 脂肪肝处理剂和体脂联素表达增强剂当候选物质具有对鞘磷脂合酶抑制活性。
-
公开(公告)号：EP2619310A2
公开(公告)日：2013-07-31
申请号：EP11784801.0
申请日：2011-09-21
发明人： MITSUTAKE, Susumu , ZAMA, Kota , IGARASHI, Yasuyuki , YOSHIDA, Tetsuya , TANAKA, Yoshikazu , TAKEMOTO, Hiroshi
IPC分类号： C12N15/113 , A61K31/712 , A61K31/713
CPC分类号： C12N15/1137 , C12N2310/11 , C12N2310/14 , C12N2310/3231 , C12Y207/08
摘要： The problem of the present invention is to prove a medicament for decreasing body weight, a medicament for decreasing visceral fat, a medicament for decreasing triglyceride in the liver, and a method for screening a medicament for ameliorating obesity and fatty liver. The problem is solved by a method comprising measuring an activity of a candidate material for inhibiting a sphingomyelin synthetase wherein if the candidate material has an activity for inhibiting a sphingomyelin synthetase, the candidate material is judged to have at least one function selected from the consisting of an anti-obesity drug, a drug for decreasing visceral fat, a drug for treating fatty liver and an agent for increasing adiponectin expression.
-
搜索结果
2 条记录 (耗时 0.069 秒)
